SEC Form 4 · accession 0001325812-18-000030
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Akshay Vaishnaw
Officer — President, R&D
Period of report
Aug 10, 2018
Accepted (ET)
Aug 14, 2018 · 6:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 13, 2018 | A | 1,724 | $0.00 | A | 12,939 | D | |
| Common Stock | Aug 13, 2018 | F | 766 | $90.95 | D | 12,173 | D | |
| Common StockF2 | Apr 16, 2018 | J | 28 | $0.00 | A | 366 | I | by Managed Account |
| Common StockF2 | Jul 10, 2018 | J | 29 | $0.00 | A | 395 | I | by Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Based Stock Option 2013 (right to buy) | $63.00 | Aug 10, 2018 | A | 10,832 | A | Aug 10, 2018 | Dec 18, 2023 | Common Stock | 10,832 | 32,500 | D |
| Performance Based Stock Option 2014 (right to buy) | $96.45 | Aug 10, 2018 | A | 11,707 | A | Aug 10, 2018 | Dec 17, 2024 | Common Stock | 11,707 | 35,125 | D |
Explanation of responses
- F1On January 4, 2016, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. The shares subject to release vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the RSU shares have vested.
- F2Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F3On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award.
- F4On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award.